Developer docs
API playgroundTry for free, no card

Search company profiles

Invus

Full company profile

uuid0000j18

Namestring
Invus
Legal namestring
The Invus Group, LLC
Websiteurl
invus.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Invus is a privately held, multi-strategy investment firm founded in 1985 as the investment arm of Artal, a European family group. Headquartered in New York with offices in Paris, Hong Kong, Miami, Jackson, and Singapore, the firm manages over $10 billion in evergreen capital and operates four platforms: Private Equity (long-term investments in transformational opportunities across consumer, technology, and life sciences, typically as sole or lead institutional partner with check sizes of $10M to $800M), Public Equity (long-only concentrated portfolio with multi-year holding periods), Invus Opportunities (global private technology investing with $2.5B+ AUM across 100+ companies in fintech, marketplace, healthcare, AI/software, and tech-enabled sectors), and Invus Financial Advisors (public equity long/short fund of funds strategy managed since 1994).

Unlike traditional PE/VC firms, Invus operates with a continuous capital structure sourced from Artal, with no predetermined fund life and no transaction or monitoring fees. Compensation is aligned entirely to realized value creation, and the same team partners with portfolio companies from investment through exit over an average duration of 10+ years. Recent investment activity has been particularly heavy in clinical-stage biotech and gene therapy (Corxel, Solid Biosciences, Ray Therapeutics, TRIANA, Lycia, Absci, Abivax, GenSight, ONWARD), with new consumer and deep-tech positions in Call Your Mother, Flexiv (robotics), Dorsia, and KNIME (open-source data science and AI).

The firm's go-to-market is primarily direct outreach to entrepreneurs and management teams rather than broad marketing, and its lean headcount of 11-50 professionals supports a global investment operation. CEO Raymond Debbane leads a senior team with deep strategy consulting backgrounds (Boston Consulting Group, McKinsey, Monitor Group) that effectively serves as free strategic advisors to portfolio companies, distinguishing Invus from capital-only financial sponsors.

Short descriptiontext

Invus is a privately held, multi-strategy investment firm managing over $10 billion in evergreen capital for parent Artal, serving as a long-term lead investor across private equity, public equity, technology (via Invus Opportunities), and fund-of-funds strategies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investing, growth equity capital, venture capital, fund of funds, investment management
Industry2 codes
1Institutional Consulting RIAs (OCIO/Endowments/Foundations/Pensions)
CodeFSAAACAGPrimaryYes
2International/Ex-U.S. Developed Equity (Active)
CodeFSAAAIAEPrimaryNo
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Private Equity / Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeManaged Services
Description

Invus generates revenue through management of private investment capital for its parent company Artal. The firm operates with an evergreen capital structure allowing long-term investment holding without forced exits. Unlike traditional PE/VC firms, they do not charge transaction or monitoring fees, with compensation aligned to realized value creation.

invus.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Invus is a privately held global investment firm that deploys long-term capital as sole or lead institutional financial partner into private and public companies across consumer, technology, and life sciences sectors. It invests across the full lifecycle — from early-stage growth to turnarounds — with check sizes ranging from under $10 million to $800 million, and operates through four strategies: Private Equity, Public Equity, Invus Opportunities (private technology), and Invus Financial Advisors (fund of funds). The firm charges no transaction or monitoring fees and aligns its compensation to realized value creation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Invus is a multi-strategy private equity and investment firm offering four distinct investment services: Private Equity (long-term investments in private companies as lead financial partner), Public Equity (long-only concentrated portfolio of public stocks), Invus Opportunities (global private technology investing with over $2.5B AUM across 100+ companies), and Invus Financial Advisors (fund of funds strategy focused on emerging hedge fund managers). The firm operates with a continuous capital structure from its founding source Artal, enabling long-term value creation without arbitrary exit timelines.

Product and service4 records
1Invus Private Equity
CategoryPrivate Equity
2Invus Public Equity
CategoryPublic Equity
3Invus Opportunities
CategoryPrivate Equity / Venture Capital (Technology)
4Invus Financial Advisors
CategoryFund of Funds / Hedge Funds
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global alternative asset manager with multi-strategy platform spanning PE, public equity, credit, and real estate. Closest comparable as a diversified alternative manager with permanent capital components, though much larger scale.

TypeBroad incumbent
Description

Global alternative asset manager with PE, credit, and public equity strategies and similar multi-region presence (US, Europe, Asia). Comparable multi-strategy global investing model.

TypeBroad incumbent
Description

Global alternative asset manager with PE, public equity, credit, and venture strategies. Comparable cross-asset platform with both PE direct investing and public equity operations.

TypeBroad incumbent
Description

Global alternative asset manager with PE, growth, impact, and public equity strategies. Comparable diversified platform and similar focus on healthcare and tech sectors.

TypeDirect peer
Description

Global growth equity investor with significant healthcare and tech focus. Comparable growth-stage, sector-agnostic direct investing model with international footprint.

TypeDirect peer
Description

Tech-focused PE firm with deep operational value-add approach. Comparable emphasis on tech and tech-enabled businesses, though Vista focuses exclusively on enterprise software.

TypeBroad incumbent
Description

Global alternative asset manager with PE, credit, and insurance balance sheet operations. Similar multi-strategy permanent capital model with comparable cross-cycle investing philosophy.

TypeBroad incumbent
Description

World's largest alternative asset manager with diversified PE, public equity, hedge fund solutions, and credit strategies. Comparable broad platform but at vastly larger scale.

TypeEmerging player
Description

Long-biased tech investor with both public equity and private equity strategies. Comparable cross-asset tech focus, though Coatue is more concentrated in software/consumer internet.

TypeEmerging player
Description

Multi-strategy fund with public and private tech investing. Comparable cross-asset tech and growth-stage approach, though shorter track record than Invus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment321 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invus

Private Equity / Investment Managementinvus.com

Invus is a privately held, multi-strategy investment firm managing over $10 billion in evergreen capital for parent Artal, serving as a long-term lead investor across private equity, public equity, technology (via Invus Opportunities), and fund-of-funds strategies globally.

What Invus does

Invus is a privately held, multi-strategy investment firm founded in 1985 as the investment arm of Artal, a European family group. Headquartered in New York with offices in Paris, Hong Kong, Miami, Jackson, and Singapore, the firm manages over $10 billion in evergreen capital and operates four platforms: Private Equity (long-term investments in transformational opportunities across consumer, technology, and life sciences, typically as sole or lead institutional partner with check sizes of $10M to $800M), Public Equity (long-only concentrated portfolio with multi-year holding periods), Invus Opportunities (global private technology investing with $2.5B+ AUM across 100+ companies in fintech, marketplace, healthcare, AI/software, and tech-enabled sectors), and Invus Financial Advisors (public equity long/short fund of funds strategy managed since 1994).

Unlike traditional PE/VC firms, Invus operates with a continuous capital structure sourced from Artal, with no predetermined fund life and no transaction or monitoring fees. Compensation is aligned entirely to realized value creation, and the same team partners with portfolio companies from investment through exit over an average duration of 10+ years. Recent investment activity has been particularly heavy in clinical-stage biotech and gene therapy (Corxel, Solid Biosciences, Ray Therapeutics, TRIANA, Lycia, Absci, Abivax, GenSight, ONWARD), with new consumer and deep-tech positions in Call Your Mother, Flexiv (robotics), Dorsia, and KNIME (open-source data science and AI).

The firm's go-to-market is primarily direct outreach to entrepreneurs and management teams rather than broad marketing, and its lean headcount of 11-50 professionals supports a global investment operation. CEO Raymond Debbane leads a senior team with deep strategy consulting backgrounds (Boston Consulting Group, McKinsey, Monitor Group) that effectively serves as free strategic advisors to portfolio companies, distinguishing Invus from capital-only financial sponsors.

Invus firmographics

Firmographics
Name
Invus
Legal name
The Invus Group, LLC
Website
https://invus.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
11–50 employees
Short description
Invus is a privately held, multi-strategy investment firm managing over $10 billion in evergreen capital for parent Artal, serving as a long-term lead investor across private equity, public equity, technology (via Invus Opportunities), and fund-of-funds strategies globally.
Ownership category
akta.pro rank

Invus industry classification

Industry
Product category
Private Equity / Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro primary industry
Institutional Consulting RIAs (OCIO/Endowments/Foundations/Pensions) (FSAAACAG)
akta.pro secondary industry
International/Ex-U.S. Developed Equity (Active) (FSAAAIAE)

Keywords

  • Private equity investing
  • Growth equity capital
  • Venture capital
  • Fund of funds
  • Investment management

Where Invus is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Invus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Management: Invus generates revenue through management of private investment capital for its parent company Artal. The firm operates with an evergreen capital structure allowing long-term investment holding without forced exits. Unlike traditional PE/VC firms, they do not charge transaction or monitoring fees, with compensation aligned to realized value creation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Invus product offering

Product offering

Core offering

Invus is a privately held global investment firm that deploys long-term capital as sole or lead institutional financial partner into private and public companies across consumer, technology, and life sciences sectors. It invests across the full lifecycle — from early-stage growth to turnarounds — with check sizes ranging from under $10 million to $800 million, and operates through four strategies: Private Equity, Public Equity, Invus Opportunities (private technology), and Invus Financial Advisors (fund of funds). The firm charges no transaction or monitoring fees and aligns its compensation to realized value creation.

Product overview

Invus is a multi-strategy private equity and investment firm offering four distinct investment services: Private Equity (long-term investments in private companies as lead financial partner), Public Equity (long-only concentrated portfolio of public stocks), Invus Opportunities (global private technology investing with over $2.5B AUM across 100+ companies), and Invus Financial Advisors (fund of funds strategy focused on emerging hedge fund managers). The firm operates with a continuous capital structure from its founding source Artal, enabling long-term value creation without arbitrary exit timelines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Invus Private Equity
  • Invus Public Equity
  • Invus Opportunities
  • Invus Financial Advisors

Companies that use Invus

Customer profile

Segments3 records

Ideal customer profiles3 records

Invus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Invus partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Invus competitors and assessment

Company assessment

Broad incumbents

  • KKR & Co Inc: Global alternative asset manager with multi-strategy platform spanning PE, public equity, credit, and real estate. Closest comparable as a diversified alternative manager with permanent capital components, though much larger scale.
  • The Carlyle Group: Global alternative asset manager with PE, credit, and public equity strategies and similar multi-region presence (US, Europe, Asia). Comparable multi-strategy global investing model.
  • Bain Capital: Global alternative asset manager with PE, public equity, credit, and venture strategies. Comparable cross-asset platform with both PE direct investing and public equity operations.
  • TPG Inc: Global alternative asset manager with PE, growth, impact, and public equity strategies. Comparable diversified platform and similar focus on healthcare and tech sectors.
  • Apollo Global Management: Global alternative asset manager with PE, credit, and insurance balance sheet operations. Similar multi-strategy permanent capital model with comparable cross-cycle investing philosophy.
  • Blackstone Inc: World's largest alternative asset manager with diversified PE, public equity, hedge fund solutions, and credit strategies. Comparable broad platform but at vastly larger scale.

Direct peers

  • General Atlantic: Global growth equity investor with significant healthcare and tech focus. Comparable growth-stage, sector-agnostic direct investing model with international footprint.
  • Vista Equity Partners: Tech-focused PE firm with deep operational value-add approach. Comparable emphasis on tech and tech-enabled businesses, though Vista focuses exclusively on enterprise software.

Emerging players

  • Coatue Management: Long-biased tech investor with both public equity and private equity strategies. Comparable cross-asset tech focus, though Coatue is more concentrated in software/consumer internet.
  • Tiger Global Management: Multi-strategy fund with public and private tech investing. Comparable cross-asset tech and growth-stage approach, though shorter track record than Invus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Invus social profiles

Digital presence

Invus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invus leadership team

Management profile

Number of profiles

Profiles14 records

Invus subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Invus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invus M&A and investment

M&A and investment

M&A1 record

Investments321 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invus

What does Invus do?

Invus is a privately held global investment firm that deploys long-term capital as sole or lead institutional financial partner into private and public companies across consumer, technology, and life sciences sectors. It invests across the full lifecycle — from early-stage growth to turnarounds — with check sizes ranging from under $10 million to $800 million, and operates through four strategies: Private Equity, Public Equity, Invus Opportunities (private technology), and Invus Financial Advisors (fund of funds). The firm charges no transaction or monitoring fees and aligns its compensation to realized value creation.

Is Invus a public or private company?

Invus is a private company. It is classified as corporate owned and is currently operating.

When was Invus founded?

Invus was founded in 1985. It employs 11 to 50 people.

Where is Invus based?

Invus is headquartered in New York, United States, in the North America region.

How does Invus make money?

One revenue line is on record: investment Management.

Who are Invus's main competitors?

Broad incumbents on record are KKR & Co Inc, The Carlyle Group, Bain Capital, TPG Inc, Apollo Global Management and Blackstone Inc. Direct peers are General Atlantic and Vista Equity Partners. Emerging players are Coatue Management and Tiger Global Management.

Does Invus have an API?

No public API is recorded for Invus.

What industry is Invus in?

Invus's product category is Private Equity / Investment Management. Its primary akta.pro industry code is FSAAACAG, Institutional Consulting RIAs (OCIO/Endowments/Foundations/Pensions), with a secondary code of FSAAAIAE, International/Ex-U.S. Developed Equity (Active). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceGenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business UpdatesGenSight Biologics reported H1 2026 IFRS revenue of €(1.2) million, down from €(0.2) million, after collecting €6.5 million in early access payments. Operating cash burn fell 37% to €1.6 million, and manufacturing transfer to Catalent was completed. The company seeks structural financing for the RECOVER Phase III trial, expected to start in H2 2027.MorningstarGenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business UpdatesGenSight Biologics reported H1 2026 interim results, collecting €6.5M in early access cash but reporting €(1.2)M IFRS revenue after rebates and a €4.3M accounting change. Operating cash burn fell 37% to €1.6M, and manufacturing transfer to Catalent was completed. The company seeks structural financing for the RECOVER Phase III trial, expected to start in H2 2027.WebrazziBeyin-bilgisayar ara yüzleri alanına odaklanan Precision, 250 milyon dolar yatırım aldıPrecision, a brain-computer interface developer, raised $250 million in a Series D round led by Pershing Square, Ackman Oxman Institute, and an undisclosed fund. The company's total funding now stands at $430 million. The funds will support expanding clinical programs, advancing FDA review of its Layer 7 technology, and commercialization efforts.FinSMEsPrecision Neuroscience Closes $250M Series D FundingPrecision Neuroscience closed a $250M Series D financing co-led by Pershing Square and the Ackman Oxman Institute. The company will use the funds to expand its clinical program, advance Layer 7 through FDA review, and build commercialization infrastructure. It has raised $430M since 2021 and completed over 100 patient procedures.Venture Capital Access OnlinePrecision Neuroscience Closes Oversubscribed $250M Series D Led by Pershing Square Inc., the Ackman Oxman Institute, and a Leading Life Sciences Investment FundPrecision Neuroscience closed an oversubscribed $250 million Series D round co-led by Pershing Square, the Ackman Oxman Institute, and an undisclosed life sciences fund. The company has raised $430 million total and performed over 100 patient procedures across 18 institutions. Funds will expand its clinical program and advance FDA review of its Layer 7 interface.BioSpaceAethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisAethlon Medical and North Immunology announced a merger to advance NOR-101, a bispecific antibody for atopic dermatitis. The deal includes an oversubscribed $180 million private placement and is expected to close in Q1 2027. Phase 1a of NOR-101 is planned for Q1 2027, with topline data expected in 2028.BiontechBioNTech Secures USD 270 Million in Series A FinancingBioNTech completed a $270 million Series A financing round led by Redmile Group, with participation from Janus Henderson, Invus, Fidelity, and others. The company will use the funds to advance its clinical pipeline of individualized immunotherapies, including mRNA and CAR-T therapies for cancer.FinSMEsLifeMine Therapeutics Raises $263M in FundingLifeMine Therapeutics raised $263M in a Series E round led by Milky Way Investments, bringing total funding to $558M. The company will use the funds to accelerate its lead program LIFE-001, including a planned Phase 2 kidney transplant study and Phase 1b islet cell transplant study.BioSpaceWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsWhitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6 million and cash of $190 million, funding operations into 2H 2028. The company continued Phase 1 enrollment for HWK-007 and HWK-016, with HWK-206 trial initiation planned for Q3 2026.PR NewswireWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsWhitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6 million and cash of $190 million as of June 30, 2026. The company continues Phase 1 trials for HWK-007 and HWK-016, with HWK-206 planned to initiate in Q3 2026. It also entered an option agreement with Hangzhou DAC and a collaboration with Biocytogen.